3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
5
NETWORK
2
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
18
Breast Neoplasms
5
Philadelphia Chromosome
4
Leukemia
4
Neoplasms
3
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid
2
Bronchiolitis Obliterans Syndrome
2
Translocation, Genetic
1
Pathologic Processes
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Hematologic Diseases
1
Bone Marrow Diseases
1
Blast Crisis
1
Advanced Breast Cancer (Parts 1 and 2)
1
Interventions
Imatinib Mesylate
15
Dasatinib
14
nilotinib
8
olverembatinib
4
asciminib
4
ponatinib
3
Cyclosporine
3
bosutinib
2
Methotrexate
2
Homoharringtonine
2
Cyclophosphamide
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
inecalcitol
1
flumatinib
1
fludarabine phosphate
1
elsulfavirine
1
Whole-Body Irradiation
1
Transplantation
1
Radiotherapy
1
Peripheral Blood Stem Cell Transplantation
1
PF-114
1
Mycophenolic Acid
1
Interferon-alpha
1
Hydroxyurea
1
Fentanyl
1
Everolimus
1
Cytarabine
1
Cord Blood Stem Cell Transplantation
1
Busulfan
1
BMS-833923
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myeloid, Chronic-Phase
×
bosutinib
×
Clear all
NCT07091019
2025-07-29
ASC4REAL-2
Novartis
Not yet recruiting
1,000 enrolled
NCT06423911
2025-06-03
POLARIS-2
Ascentage Pharma Group Inc.
Phase 3
Recruiting
285 enrolled